26 results on '"Arato T"'
Search Results
2. The unique characteristics of regulations and clinical practice to be considered in developments of regenerative medicine products in Japan
- Author
-
Sakushima, K., primary and Arato, T., additional
- Published
- 2017
- Full Text
- View/download PDF
3. Combustion method and apparatus for solid wastes using combustion residue as fuel
- Author
-
Arato, T., primary
- Published
- 2002
- Full Text
- View/download PDF
4. Analysis of low-molecular-mass proteins in cerebrospinal fluid by sodium dodecyl sulfate capillary gel electrophoresis
- Author
-
Hiraoka, A., Arato, T., Tominaga, I., Eguchi, N., Oda, H., and Urade, Y.
- Published
- 1997
- Full Text
- View/download PDF
5. Sodium dodecyl sulfate-capillary gel electrophoretic analysis of molecular mass microheterogeneity of -trace protein in cerebrospinal fluid from patients with central nervous system diseases
- Author
-
Hiraoka, A., Arato, T., Tominaga, I., Eguchi, N., Oda, H., and Urade, Y.
- Published
- 1998
- Full Text
- View/download PDF
6. Capillary electrophorefic analyses of -trace protein and other low molecular weight proteins in cerebrospinal fluid from patients with central nervous system diseases
- Author
-
Hiraoka, A., Arato, T., Tominaga, I., and Anjyo, A.
- Published
- 1997
- Full Text
- View/download PDF
7. Implementation status of pharmacological studies in the development of orphan drugs.
- Author
-
Yokoshiki S and Arato T
- Subjects
- Animals, United States, Humans, Orphan Drug Production, Drug Approval, United States Food and Drug Administration, Biomarkers, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Neoplasms drug therapy
- Abstract
Background: The nonclinical as well as clinical development of orphan drugs is difficult, owing to unknown pathophysiology and the absence of animal models. Both, the U.S. Food and Drug Administration (FDA) Guidance and European Medicines Agency (EMA) Guidelines, for orphan drug development describe non-clinical studies, but lack specific information, such as animal species and study design. Against this background, this study aimed to elucidate efficient methods for evaluating nonclinical efficacy based on a review report of orphan drugs approved in Japan., Results: A total of 184 orphan drugs, including 84 anticancer and 100 non-anticancer drugs, approved in Japan from January 2010 to December 2019 were investigated. Some anticancer drugs progressed to clinical development without distinct efficacy data in nonclinical studies. Patient-derived cells have been used for some drugs due to a lack of established cell lines. Cells used for non-clinical studies were devised for drugs indicated for cancers resistant to prior therapies, tumours with specific amino acid mutations in the target molecules, and solid tumours with specific biomarkers. For some non-anticancer drugs, similar disease animal models and normal animals were used for evaluation, since animal models did not exist. Biomarkers have been used specifically for evaluation in normal animals and as endpoints in some clinical trials., Conclusions: It was possible to evaluate drug efficacy by flexibly designing nonclinical studies according to disease characteristics for potentials orphan drugs. These approaches, which are not described in detail in the EMA Guideline or FDA Guidance, may thus lead to approval., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
8. Cell and gene therapy approvals in Japan and the need for international harmonization.
- Author
-
Arato T and Nomura K
- Subjects
- Japan, International Cooperation, Drug Industry
- Published
- 2024
- Full Text
- View/download PDF
9. Protocol for treating lumbar spinal canal stenosis with a combination of ultrapurified, allogenic bone marrow-derived mesenchymal stem cells and in situ-forming gel: a multicentre, prospective, double-blind randomised controlled trial.
- Author
-
Sudo H, Miyakoshi T, Watanabe Y, Ito YM, Kahata K, Tha KK, Yokota N, Kato H, Terada T, Iwasaki N, Arato T, Sato N, and Isoe T
- Subjects
- Humans, Prospective Studies, Bone Marrow, Constriction, Pathologic, Spinal Canal, Treatment Outcome, Lumbar Vertebrae surgery, Randomized Controlled Trials as Topic, Multicenter Studies as Topic, Intervertebral Disc Degeneration surgery, Spinal Stenosis surgery, Mesenchymal Stem Cells
- Abstract
Introduction: In patients with combined lumbar spinal canal stenosis (LSCS), a herniated intervertebral disc (IVD) that compresses the dura mater and nerve roots is surgically treated with discectomy after laminoplasty. However, defects in the IVD after discectomy may lead to inadequate tissue healing and predispose patients to the development of IVD degeneration. Ultrapurified stem cells (rapidly expanding clones (RECs)), combined with an in situ-forming bioresorbable gel (dMD-001), have been developed to fill IVD defects and prevent IVD degeneration after discectomy. We aim to investigate the safety and efficacy of a new treatment method in which a combination of REC and dMD-001 is implanted into the IVD of patients with combined LSCS., Methods and Analysis: This is a multicentre, prospective, double-blind randomised controlled trial. Forty-five participants aged 20-75 years diagnosed with combined LSCS will be assessed for eligibility. After performing laminoplasty and discectomy, participants will be randomised 1:1:1 into the combination of REC and dMD-001 (REC-dMD-001) group, the dMD-001 group or the laminoplasty and discectomy alone (control) group. The primary outcomes of the trial will be the safety and effectiveness of the procedure. The effectiveness will be assessed using visual analogue scale scores of back pain and leg pain as well as MRI-based estimations of morphological and compositional quality of the IVD tissue. Secondary outcomes will include self-assessed clinical scores and other MRI-based estimations of compositional quality of the IVD tissue. All evaluations will be performed at baseline and at 1, 4, 12, 24 and 48 weeks after surgery., Ethics and Dissemination: This study was approved by the ethics committees of the institutions involved. We plan to conduct dissemination of the outcome data by presenting our data at national and international conferences, as well as through formal publication in a peer-reviewed journal., Trial Registration Number: jRCT2013210076., Competing Interests: Competing interests: HS is listed as an inventor on a patent application related to this work., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
10. Biologically Equivalent Dose Comparison Between Magnetic Resonance-Guided Adaptive and Computed Tomography-Guided Internal Target Volume-Based Stereotactic Body Radiotherapy for Liver Tumors.
- Author
-
Yoda K, Sato A, Miyake Y, Arato T, and Starbuck W
- Abstract
Background and aim Magnetic resonance (MR) imaging has been increasingly adopted in the field of radiotherapy, and the most advanced MR image-guided radiotherapy is known as MR-guided online adaptive radiotherapy (MRgOART), which integrates MRI and linac systems. Few attempts have yet been made to directly compare treatment outcomes between the MRgOART and standard computed tomography (CT)-guided radiotherapy (CTgRT). Besides, it is reported that the biologically equivalent dose (BED) may be a good predictor of the local control (LC) and the overall survival (OS) for liver tumors. The purpose of this study is to compare the BEDs between the MRgOART and the CTgRT by way of virtual isotoxic planning for liver tumors. The hypothesis of this study is therefore that the MRgOART increases LC and OS as compared to the CTgRT. Materials and methods Using the five patient cases available, isotoxic planning was performed. For CTgRT, an internal target volume (ITV) was defined, and the planning target volume (PTV) was created by adding an isotropic margin of 10 mm. For MRgRT, a gross tumor volume (GTV) was defined, and the PTV was created by adding an isotropic margin of 5 mm. Each tumor size was virtually adjusted so that the CTgRT plans resulted in BED <100 Gy under the condition that the nearest organs at risk receive maximum tolerated doses. Subsequently, the BED was recalculated for MRgOART plans with the adjusted tumor size. Results and discussion It was found that the BEDs of the MRgOART plans always exceeded 100 Gy and were approximately 20 Gy larger than those of the corresponding CTgRT plans. Literature shows that superior overall survival rates for liver tumors were observed when BED was >100 Gy as compared to BED <100 Gy, suggesting that MR-guided adaptive planning may potentially lead to better treatment outcomes for liver tumors. We have also observed a case where the duodenum largely moved and abutted the liver after the CT images were acquired, indicating a significant disadvantage of the standard CTgRT because such abutting is not observable by the cone-beam CT immediately before treatment. Conclusion A highly accelerated evidence-creation procedure to suggest the clinical superiority of MRgOART has been arguably proposed with promising results. The sample size is small and limits the extent to which the findings in this study can be generalized. Further virtual clinical trials within the radiotherapy community are awaited with more clinical outcomes data., Competing Interests: The authors have declared financial relationships, which are detailed in the next section., (Copyright © 2023, Yoda et al.)
- Published
- 2023
- Full Text
- View/download PDF
11. Challenges for Streamlining the Development of Biosimilars: A Japanese Perspective.
- Author
-
Arato T
- Subjects
- Humans, East Asian People, Drug Industry, Biosimilar Pharmaceuticals
- Published
- 2023
- Full Text
- View/download PDF
12. Exploratory clinical trial on the safety and capability of dMD-001 in lumbar disc herniation: Study protocol for a first-in-human pilot study.
- Author
-
Yamada K, Kenichiro M, Ito YM, Inage F, Isoe T, Yokota N, Sugita O, Sato N, Tha KK, Iwasaki N, Arato T, and Sudo H
- Abstract
Herniated nucleus pulposus (NP), one of the most common diseases of the spine, is surgically treated by removing the sequestered NP. However, intervertebral disc (IVD) defects may remain after discectomy, leading to inadequate tissue healing and predisposing patients to IVD degeneration. An acellular, bioresorbable, ultra-purified alginate (UPAL) gel (dMD-001) implantation system can be used to fill any IVD defects in order to prevent IVD degeneration after discectomy. This first-in-human pilot study aims to determine the feasibility, safety, and perceived patient response to a combined treatment involving discectomy and UPAL gel implantation for herniated NP. We designed a one-arm, double-centre, open-label, pilot trial. The study started in November 2018 and will run until a sample of 40 suitable participants is established. Patients aged 20-49 years, diagnosed with isolated lumbar IVD herniation and scheduled for discectomy represent suitable candidates. All eligible participants who provide informed consent undergo standard discectomy followed by UPAL gel implantation. The primary outcomes of the trial will be the feasibility and safety of the procedure. Secondary outcomes will include self-assessed clinical scores and magnetic resonance imaging-based measures of morphological and compositional quality of the IVD tissue. Initial outcomes will be published at 24 weeks. Analysis of feasibility and safety will be performed using descriptive statistics. Both intention-to-treat and per-protocol analyses of treatment trends of effectiveness will be conducted., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
13. Considerations of the Japanese Research Working Group for the ICH S6 & Related Issues Regarding Nonclinical Safety Assessments of Oligonucleotide Therapeutics: Comparison with Those of Biopharmaceuticals.
- Author
-
Hirabayashi Y, Maki K, Kinoshita K, Nakazawa T, Obika S, Naota M, Watanabe K, Suzuki M, Arato T, Fujisaka A, Fueki O, Ito K, and Onodera H
- Subjects
- Biological Products adverse effects, Guidelines as Topic, Humans, Japan, Oligonucleotides adverse effects, Biological Products therapeutic use, Drug Evaluation, Preclinical, Oligonucleotides therapeutic use
- Abstract
This white paper summarizes the current consensus of the Japanese Research Working Group for the ICH S6 & Related Issues (WGS6) on strategies for the nonclinical safety assessment of oligonucleotide-based therapeutics (ONTs), specifically focused on the similarities and differences to biotechnology-derived pharmaceuticals (biopharmaceuticals). ONTs, like biopharmaceuticals, have high species and target specificities. However, ONTs have characteristic off-target effects that clearly differ from those of biopharmaceuticals. The product characteristics of ONTs necessitate specific considerations when planning nonclinical studies. Some ONTs have been approved for human use and many are currently undergoing nonclinical and/or clinical development. However, as ONTs are a rapidly evolving class of drugs, there is still much to learn to achieve optimal strategies for the development of ONTs. There are no formal specific guidelines, so safety assessments of ONTs are principally conducted by referring to published white papers and conventional guidelines for biopharmaceuticals and new chemical entities, and each ONT is assessed on a case-by-case basis. The WGS6 expects that this report will be useful in considering nonclinical safety assessments and developing appropriate guidelines specific for ONTs.
- Published
- 2021
- Full Text
- View/download PDF
14. Exploring Factors Affecting the Acceptance of Genetically Edited Food Among Youth in Japan.
- Author
-
Farid M, Cao J, Lim Y, Arato T, and Kodama K
- Subjects
- Adolescent, Female, Food, Humans, Japan, Male, Consumer Behavior, Food, Genetically Modified, Health Knowledge, Attitudes, Practice
- Abstract
Genetically edited food utilizes new techniques that may decrease all of the risks associated with genetically modified food, or "GMO" food. Safety and labeling regulations for genetically edited food are still new, and it is challenging for the consumer to differentiate it from conventional food. Although genetically edited food has the potential for reducing the risks associated with the gene introduction process, consumer perceptions toward it are still unclear. The research has compared the regulations governing GMO food and genetically edited food in Japan, Europe, and the United States. We found that the genetically edited food regulations in Japan are the most science-based, in the meaning that genetically edited food products are allowed to be sold without any safety evaluation. Based on the difference among regions, we further studied the potential acceptance level for such products among Japanese consumers, where regulation seemed science-based as policy. To understand the factors that may affect the adoption of genetically edited food among youth in Japan, we utilized the structural equation modeling (SEM) method with 180 surveys of Japanese university students to measure six factors: Knowledge, Attitude Towards Technology, Perceived Benefits, Perceived Risks, Trust, and Willingness to Purchase. The survey was conducted twice with an intervention in the middle to measure the effect of science communication, and we found significant differences when comparing the two datasets. The results of this survey indicate the importance of increasing knowledge and the positive role of science communication in increasing the adoption and trust of biotechnology products, such as genetically edited food., Competing Interests: The authors declare no conflict of interest.
- Published
- 2020
- Full Text
- View/download PDF
15. Accelerating Cell Therapy for Stroke in Japan: Regulatory Framework and Guidelines on Development of Cell-Based Products.
- Author
-
Houkin K, Shichinohe H, Abe K, Arato T, Dezawa M, Honmou O, Horie N, Katayama Y, Kudo K, Kuroda S, Matsuyama T, Miyai I, Nagata I, Niizuma K, Sakushima K, Sasaki M, Sato N, Sawanobori K, Suda S, Taguchi A, Tominaga T, Yamamoto H, Yamashita T, and Yoshimine T
- Subjects
- Cell- and Tissue-Based Therapy standards, Guidelines as Topic, Humans, Japan, Stem Cell Transplantation legislation & jurisprudence, Stroke therapy, Cerebral Infarction therapy, Regenerative Medicine legislation & jurisprudence, Stem Cell Transplantation standards
- Published
- 2018
- Full Text
- View/download PDF
16. Research on advanced intervention using novel bone marrOW stem cell (RAINBOW): a study protocol for a phase I, open-label, uncontrolled, dose-response trial of autologous bone marrow stromal cell transplantation in patients with acute ischemic stroke.
- Author
-
Shichinohe H, Kawabori M, Iijima H, Teramoto T, Abumiya T, Nakayama N, Kazumata K, Terasaka S, Arato T, and Houkin K
- Subjects
- Bone Marrow Cells, Female, Humans, Magnetic Resonance Imaging, Male, Mesenchymal Stem Cells pathology, Research Design, Bone Marrow Transplantation methods, Brain Ischemia therapy, Stroke therapy
- Abstract
Background: Stroke is a leading cause of death and disability, and despite intensive research, few treatment options exist. However, a recent breakthrough in cell therapy is expected to reverse the neurological sequelae of stroke. Although some pioneer studies on the use of cell therapy for treating stroke have been reported, certain problems remain unsolved. Recent studies have demonstrated that bone marrow stromal cells (BMSCs) have therapeutic potential against stroke. We investigated the use of autologous BMSC transplantation as a next-generation cell therapy for treating stroke. In this article, we introduce the protocol of a new clinical trial, the Research on Advanced Intervention using Novel Bone marrOW stem cell (RAINBOW)., Methods/design: RAINBOW is a phase 1, open-label, uncontrolled, dose-response study, with the primary aim to determine the safety of the autologous BMSC product HUNS001-01 when administered to patients with acute ischemic stroke. Estimated enrollment is 6-10 patients suffering from moderate to severe neurological deficits. Approximately 50 mL of the bone marrow is extracted from the iliac bone of each patient 15 days or later from the onset. BMSCs are cultured with allogeneic human platelet lysate (PL) as a substitute for fetal calf serum and are labeled with superparamagnetic iron oxide for cell tracking using magnetic resonance imaging (MRI). HUNS001-01 is stereotactically administered around the area of infarction in the subacute phase. Each patient will be administered a dose of 20 or 50 million cells. Neurological scoring, MRI for cell tracking,
18 F-fuorodeoxyglucose positron emission tomography, and123 I-Iomazenil single-photon emission computed tomography will be performed for 1 year after the administration., Discussion: This is a first-in-human trial for HUNS001-01 to the patients with acute ischemic stroke. We expect that intraparenchymal injection can be a more favorable method for cell delivery to the lesion and improvement of the motor function than intravenous infusion. Moreover, it is expected that the bio-imaging techniques can clarify the therapeutic mechanisms., Trial Registration: The trial was registered at The University Hospital Medical Information Network on February 22, 2017 (UNIN ID: UMIN000026130 ). The findings of this trial will be disseminated to patients and through peer-reviewed publications and international presentations.- Published
- 2017
- Full Text
- View/download PDF
17. Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.
- Author
-
Maeda K, Kaneko M, Narukawa M, and Arato T
- Subjects
- Humans, Japan, Rare Diseases drug therapy, Retrospective Studies, Orphan Drug Production methods
- Abstract
Background: The unmet medical needs of individuals with very rare diseases are high. The clinical trial designs and evaluation methods used for 'regular' drugs are not applicable in the clinical development of ultra-orphan drugs (<1000 patients) in many cases. In order to improve the clinical development of ultra-orphan drugs, we examined several points regarding the efficient evaluations of drug efficacy and safety that could be conducted even with very small sample sizes, based on the review reports of orphan drugs approved in Japan., Results: The clinical data packages of 43 ultra-orphan drugs approved in Japan from January 2001 to December 2014 were investigated. Japanese clinical trial data were not included in the clinical data package for eight ultra-orphan drugs, and non-Japanese clinical trial data were included for six of these eight drug. Japanese supportive data that included retrospective studies, published literature, clinical research and Japanese survey results were clinical data package attachments in 22 of the 43 ultra-orphan drugs. Multinational trials were conducted for three ultra-orphan drugs. More than two randomized controlled trials (RCTs) were conducted for only 11 of the 43 ultra-orphan drugs. The smaller the number of patients, the greater the proportion of forced titration and optional titration trials were conducted. Extension trials were carried out for enzyme preparations and monoclonal antibodies with high ratio. Post-marketing surveillance of all patients was required in 36 of the 43 ultra-orphan drugs. For ultra-orphan drugs, clinical endpoints were used as the primary efficacy endpoint of the pivotal trial only for two drugs. The control groups in RCTs were classified as follows: placebo groups different dosage groups, and active controls groups. Sample sizes have been determined on the basis of feasibility for some ultra-orphan drugs. We provide "Draft Guidance on the Clinical Development of Ultra-Orphan Drugs" based on this research., Conclusions: The development of ultra-orphan drugs requires various arrangements regarding evidence collection, data sources and the clinical trial design. We expect that this draft guidance is useful for ultra-orphan drugs developments in future.
- Published
- 2017
- Full Text
- View/download PDF
18. Japanese regulation of biosimilar products: past experience and current challenges.
- Author
-
Arato T
- Subjects
- Drug Design, European Union, Guidelines as Topic, Humans, Japan, Legislation, Drug, United States, Biological Products standards, Biosimilar Pharmaceuticals standards, Drug Approval legislation & jurisprudence
- Abstract
Seven biosimilar products have been approved in Japan since the March 2009 publication of the 'Guideline for quality, safety and efficacy assurance of biosimilar products' by the Ministry of Health, Labor and Welfare (MHLW). Four years previously, the 'Guideline on similar biological medicinal products' was issued in the European Union (EU), and 13 products as of February 2016 have been approved as biosimilar. The US Food and Drug Administration (FDA) approved the first biosimilar product in the US in March 2015 and final Guidance was issued at the end of April 2015. Over the past decade, the challenges regarding the development of biosimilar products have been discussed extensively. In this article, the data packages of biosimilar products in Japan are compared with those overseas in order to clarify the concepts used by the Japanese regulatory authority, i.e., the Pharmaceuticals and Medical Devices Agency (PMDA). The challenges in the development of biosimilar products in Japan are also addressed., (© 2016 The British Pharmacological Society.)
- Published
- 2016
- Full Text
- View/download PDF
19. [Industry-government - academia cooperation center for medical innovation in Hokkaido University].
- Author
-
Kodama KB and Arato T
- Subjects
- Cooperative Behavior, Education, Medical, Education, Pharmacy, Japan, Drug Discovery, Government, Industry, Universities
- Published
- 2015
- Full Text
- View/download PDF
20. Experience of reviewing the follow-on biologics including Somatropin and erythropoietin in Japan.
- Author
-
Arato T and Yamaguchi T
- Subjects
- Drug Packaging legislation & jurisprudence, Drug Packaging methods, Female, Follow-Up Studies, Humans, Japan, Male, Drug Evaluation methods, Erythropoietin, Guidelines as Topic, Human Growth Hormone, Product Surveillance, Postmarketing, Recombinant Proteins
- Abstract
To share the experience of reviewing clinical data required for the licensing of follow-on biologic products (biosimilar products and similar biotherapeutical products as EU and WHO terminology, respectively) in Japan, the data packages of two follow-on biologics, "Somatropin BS s.c. [Sandoz] (Omnitrope®)" and "Epoetin alfa BS [JCR]", which have been recently approved in Japan according to the "Guidelines for the Quality, Safety and Efficacy Assurance of Follow-on Biologics" published on March 4th 2009, are described. The clinical data package and indication of Somatropin BS/Omnitrope(®) were different in each country. In case of Epoetin alfa BS [JCR], non-clinical and clinical data-package was different from those of erythropoietin biosimilar products approved in EU. Submission of post-marketing surveillance plans for both products was required. Even though there seem to be differences in data requirements by each national regulatory authority, the accumulation of experience will provide the rationale and consensus on how to design the clinical trials for follow-on biologics., (Copyright © 2011. Published by Elsevier Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
21. Quality, safety and efficacy of follow-on biologics in Japan.
- Author
-
Yamaguchi T and Arato T
- Subjects
- Guidelines as Topic, Humans, Japan, Product Surveillance, Postmarketing standards, Product Surveillance, Postmarketing trends, Quality Control, Drug Approval legislation & jurisprudence, Drug Industry legislation & jurisprudence, Drug Industry standards, Pharmaceutical Preparations standards
- Abstract
Recently, WHO, EU, Japan and Canada have published guidelines on biosimilar/follow-on biologics. While there seems to be no significant difference in the general concept in these guidelines, the data to be submitted for product approval are partially different. Differences have been noted in the requirements for comparability studies on stability, prerequisites for reference product, or for the need of comparability exercise for determination of process-related impurities. In Japan, there have been many discussions about the amount and extent of data for approval of follow-on biologics. We try to clarify the scientific background and rational for regulatory pathway of biosimilar/follow-on biologics in Japan in comparison with the guidelines available from WHO, EU and Canada. In this article, we address and discuss the scientific background underlying these differences to facilitate the harmonization of follow-on biologic principles in the guidelines in future., (Copyright © 2011. Published by Elsevier Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
22. A comparative study of monosaccharide composition analysis as a carbohydrate test for biopharmaceuticals.
- Author
-
Harazono A, Kobayashi T, Kawasaki N, Itoh S, Tada M, Hashii N, Ishii A, Arato T, Yanagihara S, Yagi Y, Koga A, Tsuda Y, Kimura M, Sakita M, Kitamura S, Yamaguchi H, Mimura H, Murata Y, Hamazume Y, Sato T, Natsuka S, Kakehi K, Kinoshita M, Watanabe S, and Yamaguchi T
- Subjects
- Amino Sugars analysis, Amino Sugars standards, Biological Products standards, Chromatography, High Pressure Liquid methods, Chromatography, High Pressure Liquid standards, Chromatography, Ion Exchange methods, Chromatography, Ion Exchange standards, Erythropoietin chemistry, Excipients, Glycosylation, Monosaccharides standards, Recombinant Proteins, Reference Standards, Reproducibility of Results, Sialic Acids analysis, Sialic Acids standards, Tissue Plasminogen Activator chemistry, Biological Products chemistry, Monosaccharides analysis
- Abstract
The various monosaccharide composition analysis methods were evaluated as monosaccharide test for glycoprotein-based pharmaceuticals. Neutral and amino sugars were released by hydrolysis with 4-7N trifluoroacetic acid. The monosaccharides were N-acetylated if necessary, and analyzed by high-performance liquid chromatography (HPLC) with fluorometric or UV detection after derivatization with 2-aminopyridine, ethyl 4-aminobenzoate, 2-aminobenzoic acid or 1-phenyl-3-methyl-5-pyrazolone, or high pH anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD). Sialic acids were released by mild acid hydrolysis or sialidase digestion, and analyzed by HPLC with fluorometric detection after derivatization with 1,2-diamino-4,5-methylenedioxybenzene, or HPAEC-PAD. These methods were verified for resolution, linearity, repeatability, and accuracy using a monosaccharide standard solution, a mixture of epoetin alfa and beta, and alteplase as models. It was confirmed that those methods were useful for ensuring the consistency of glycosylation. It is considered essential that the analytical conditions including desalting, selection of internal standards, release of monosaccharides, and gradient time course should be determined carefully to eliminate interference of sample matrix. Various HPLC-based monosaccharide analysis methods were evaluated as a carbohydrate test for glycoprotein pharmaceuticals by an inter-laboratory study., (Copyright © 2011 The International Association for Biologicals. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
23. Sodium dodecyl sulfate-capillary gel electrophoretic analysis of molecular mass microheterogeneity of beta-trace protein in cerebrospinal fluid from patients with central nervous system diseases.
- Author
-
Hiraoka A, Arato T, Tominaga I, Eguchi N, Oda H, and Urade Y
- Subjects
- Adult, Aged, Central Nervous System Diseases cerebrospinal fluid, Cerebrospinal Fluid Proteins analysis, Cohort Studies, Female, Humans, Lipocalins, Male, Middle Aged, Myelin Basic Protein cerebrospinal fluid, Spinal Puncture, Beta-Globulins cerebrospinal fluid, Central Nervous System Diseases diagnosis, Electrophoresis, Capillary methods, Intramolecular Oxidoreductases, Sodium Dodecyl Sulfate chemistry
- Abstract
Molecular mass (M(r)) microheterogeneity of beta-trace protein (beta TP) in cerebrospinal fluid (CSF) from patients with various neurological disorders was analyzed by sodium dodecyl sulfate capillary gel electrophoresis. Under the conditions employed, beta TP with a M(r) distribution of 23,000-30,000 was roughly separated into two subfractions containing the major peaks with M(r) of 26,000 and 28,500, respectively. The peak area ratios of the two subfractions of the electropherograms varied among the samples examined, and elevation in the total beta TP level in the CSF from patients with organic diseases in the central nervous system (CNS) was often accompanied by changes in the ratios of the subfractions. The quantitative changes in the subfraction level in CSF beta TP are considered to reflect the pathological alterations in the CNS.
- Published
- 1998
- Full Text
- View/download PDF
24. Capillary electrophoretic analyses of beta-trace protein and other low molecular weight proteins in cerebrospinal fluid from patients with central nervous system diseases.
- Author
-
Hiraoka A, Arato T, Tominaga I, and Anjyo A
- Subjects
- Humans, Isoelectric Focusing, Lipocalins, Mental Disorders cerebrospinal fluid, Molecular Weight, Reproducibility of Results, Sodium Dodecyl Sulfate, Surface-Active Agents, Beta-Globulins cerebrospinal fluid, Central Nervous System Diseases cerebrospinal fluid, Cerebrospinal Fluid Proteins cerebrospinal fluid, Electrophoresis, Capillary, Intramolecular Oxidoreductases
- Abstract
Ordinary capillary-zone electrophoresis (CZE), as well as CZE in a sodium dodecylsulfate-containing polymer solution (SDS-CZE) and capillary isoelectrofocusing (CIEF), was applied to the analysis of low molecular weight proteins in cerebrospinal fluid (CSF) from patients with various neuropsychiatric disorders. Under the CZE conditions employed, a peaks of beta-trace protein (beta TP), which is the most abundant low MW protein in CSF, was clearly detected on the electropherograms of all the samples examined, and the CSF beta TP level could be tentatively determined using allylamine added at a constant concentration as the internal standard. The results revealed that beta TP in CSF was non-specifically increased in organic disease in the central nervous system (CNS), especially in ones giving severe physical damage to the brain tissues. On the other hand, SDS-CZE allowed us to determine simultaneously the CSF minor low MW proteins other than beta TP, such as beta 2-microglobulin, gamma-trace protein, myelin basic protein, etc., while the CIEF electropherograms suggested that beta TP were separated into several fractions with the different PI values. These capillary electrophoresis systems seem to be powerful as aids in the biochemical examinations of beta TP and other low molecular weight proteins in CSF from patients with CNS diseases.
- Published
- 1997
- Full Text
- View/download PDF
25. Reduction in blood free carnitine levels in association with changes in sodium valproate (VPA) disposition in epileptic patients treated with VPA and other anti-epileptic drugs.
- Author
-
Hiraoka A, Arato T, and Tominaga I
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Valproic Acid adverse effects, Anticonvulsants pharmacokinetics, Carnitine blood, Epilepsy drug therapy, Valproic Acid pharmacokinetics
- Abstract
Reduction in the blood free carnitine (FC) level as a side effect of sodium valproate (VPA) given epileptic patients was pharmacokinetically studied in connection with changes in the VPA disposition. The serum FC level in patients taking at least one of phenobarbital (PB), phenytoin (PHT) and/or carbamazepine (CBZ) in addition to VPA was significantly lower than that in the controls given only these other anti-epileptic drugs (AEDs). Patients medicated only with VPA also tended to have a lower serum FC level than the controls, although the difference was not significant. Among all the patients taking VPA with or without other AED(s), a significantly positive correlation was observed between the serum FC level and the value of dose and level ratio (L/D) of VPA, indicating that both the serum FC concentration and the L/D value of VPA were remarkably reduced in those patients receiving both medications. These results suggested that reduction in the blood FC level as a side effect of VPA reflected FC deficiency associated with the accelerated degradation of VPA in liver; such a condition appears to result from medication with VPA and other AED(s) which induce(s) enzyme(s) for the VPA metabolism.
- Published
- 1997
- Full Text
- View/download PDF
26. Capillary zone electrophoretic determination of organic acids in cerebrospinal fluid from patients with central nervous system diseases.
- Author
-
Hiraoka A, Akai J, Tominaga I, Hattori M, Sasaki H, and Arato T
- Subjects
- Cerebral Infarction cerebrospinal fluid, Humans, Lactic Acid, Meningitis, Bacterial cerebrospinal fluid, Pyruvic Acid, Spectrophotometry, Ultraviolet, Brain Diseases cerebrospinal fluid, Electrophoresis methods, Lactates cerebrospinal fluid, Pyruvates cerebrospinal fluid
- Abstract
Organic acids in cerebrospinal fluid (CSF) from patients with various central nervous system (CNS) diseases were determined by capillary zone electrophoresis (CZE). Under one of the two sets of conditions employed, several anionic components of CSF were separated into corresponding peaks on the electropherograms and determined. The other conditions employed were also useful in measurement of the lactate contents in CSF. The CSF levels of lactate and pyruvate and the ratios of lactate to pyruvate were elevated in patients with cerebral infarction and bacterial meningitis, whereas CSF ascorbate was reduced mainly in inflammatory disorders of the CNS. The results showed that CZE can become a powerful tool in the biochemical diagnosis of CNS diseases.
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.